Search results

Order by most recent / most popular / relevance

Results: 1-10 of 36

Universities abroad experiment with no-fee licensing to drive biotech partnerships

Shook Hardy & Bacon LLP
-
Australia, Canada, European Union, United Kingdom, USA
-
May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

IP challenges for the personalised medicines industry - gene claims (part 1)

Barker Brettell LLP
-
European Union, United Kingdom, USA
-
May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical

Dispelling the Myriad gene patent harmonization myth

Foley & Lardner LLP
-
Australia, Canada, European Union, France, Germany, Japan, USA
-
April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Biological deposits and priority

Marks & Clerk LLP
-
European Union, USA
-
April 23 2013

As a result of decision T010709, issued by an EPO Technical Board of Appeal on 12 July 2012, practitioners outside Europe and especially in the US

Overview of patent-statutory subject matter in biotechnology

CCPIT Patent & Trademark Law Office
-
China, European Union, Japan, USA
-
April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound

E.U. way ahead of the game on telehealth

Epstein Becker Green
-
European Union, USA
-
March 21 2013

Telehealth is expanding rapidly outside of the U.S. in both developed and developing countries. Not surprisingly, the expanded use of telehealth

When food production leads to prosecution

Davis Wright Tremaine LLP
-
European Union, USA
-
March 6 2013

Over the last few weeks, two big stories have made headlines in the food industry. Beginning in early February, news media across Europe began

Patent claims for ‘personalised medicines’

Mewburn Ellis LLP
-
European Union, USA
-
February 7 2013

As previously reported the US Supreme Court, in Mayo v. Prometheus, recently invalidated Prometheus's diagnostic claims - directed to a method of

Methods of medical treatment claims issues in Canada, US and Europe

Gowling Lafleur Henderson LLP
-
Canada, European Union, USA
-
November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

European Commission ups the cost of paying for delay

King & Wood Mallesons
-
Australia, European Union, USA
-
August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

next >

Search results

Universities abroad experiment with no-fee licensing to drive biotech partnerships

IP challenges for the personalised medicines industry - gene claims (part 1)

Dispelling the Myriad gene patent harmonization myth

Biological deposits and priority

Overview of patent-statutory subject matter in biotechnology

E.U. way ahead of the game on telehealth

When food production leads to prosecution

Patent claims for ‘personalised medicines’

Methods of medical treatment claims issues in Canada, US and Europe

European Commission ups the cost of paying for delay

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea